ADRB2 and cancer: Specifically, administration of β−AR antagonists in combination with anti-cancer therapies resulted in a median PFS of 9 months verses previous reports of 3 to 6 months (Figure 3A), and a median OS of 36 months verses documented reports of 12 months (Figure 3B).